A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Sponsor: Merck Sharp & Dohme LLC
Aberdeen, SD · Mitchell, SD · Pierre, SD · +60 more sites